Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 t-haNK, NAI (Anktiva), and Cetuximab in Recurrent/Metastatic HNSCC
NCT06239220Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial of PD-L1 t-haNK and nogapendekin alfa inbakicept in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 1 year. Started Feb 2024; status: recruiting.
02
Drugs
PD-L1 t-haNKnogapendekin alfa inbakicept
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06239220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239220.